Allergan fails to dodge pay-for-delay claim

Ben Remaly

20 September 2018

A federal judge has ruled that plaintiffs plausibly claimed harm from Allergan’s alleged attempts to block market entry of a generic dry-eye medication.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Senior news reporter, Global Competition Review

[email protected]

Get unlimited access to all Global Competition Review content